Moderna Expects 6 Major Vaccine Launches In Next Few Years
11 Abril 2023 - 9:21AM
Dow Jones News
By Dean Seal
Moderna Inc. expects to launch six major vaccine products in the
next few years.
The vaccine maker said Tuesday that it is expanding and
advancing its pipeline of mRNA-based vaccines to include candidates
that target enteric viruses, such as norovirus, as well as Lyme
disease, which would be the company's first bacterial vaccine.
Chief Executive Stéphane Bancel said Moderna is developing its
first investigational vaccine against seasonal flu, known as
mRNA-1010, which has produced "consistently strong immunogenicity
results" against the Influenza A virus.
The company has also started dosing patients in a Phase 3 trial
of its next-generation, refrigerator-stable Covid-19 vaccine
candidate, dubbed mRNA-1283. Moderna said the annual global endemic
Covid-19 booster market alone is estimated to be about $15
billion.
Moderna also provided updates on Tuesday about its respiratory
and latent virus portfolios, saying that it expects to produce
between $8 billion and $15 billion from respiratory product sales
in 2027.
Shares were down 4.8% at $152.50 in premarket trading.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
April 11, 2023 08:06 ET (12:06 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024